Supernus Pharmaceuticals, Inc. (SUPN)
USD 35.46
(-2.1%)
USD 35.46
(-2.1%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.31 Million USD | -97.83% |
| 2022 | 60.71 Million USD | 13.64% |
| 2021 | 53.42 Million USD | -57.92% |
| 2020 | 126.95 Million USD | 12.29% |
| 2019 | 113.05 Million USD | 1.86% |
| 2018 | 110.99 Million USD | 93.76% |
| 2017 | 57.28 Million USD | -37.2% |
| 2016 | 91.22 Million USD | 550.83% |
| 2015 | 14.01 Million USD | -29.47% |
| 2014 | 19.87 Million USD | 121.54% |
| 2013 | -92.27 Million USD | -99.36% |
| 2012 | -46.28 Million USD | -182.65% |
| 2011 | 56 Million USD | 245.6% |
| 2010 | -38.46 Million USD | -8461.52% |
| 2009 | 460 Thousand USD | 101.37% |
| 2008 | -33.48 Million USD | -93.83% |
| 2007 | -17.27 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 19.91 Million USD | 15961.29% |
| 2024 Q3 | 38.49 Million USD | 93.3% |
| 2024 Q1 | 124 Thousand USD | -89.45% |
| 2023 Q2 | -831 Thousand USD | -104.9% |
| 2023 Q1 | 16.94 Million USD | -33.49% |
| 2023 FY | 1.31 Million USD | -97.83% |
| 2023 Q4 | 1.17 Million USD | 107.35% |
| 2023 Q3 | -15.97 Million USD | -1822.5% |
| 2022 Q4 | 25.48 Million USD | 1356.89% |
| 2022 FY | 60.71 Million USD | 13.64% |
| 2022 Q3 | 1.74 Million USD | -77.76% |
| 2022 Q1 | 25.61 Million USD | 948.98% |
| 2022 Q2 | 7.86 Million USD | -69.3% |
| 2021 Q2 | 23.72 Million USD | 316.68% |
| 2021 FY | 53.42 Million USD | -57.92% |
| 2021 Q4 | 2.44 Million USD | -88.67% |
| 2021 Q1 | 5.69 Million USD | -81.49% |
| 2021 Q3 | 21.56 Million USD | -9.12% |
| 2020 Q3 | 39.99 Million USD | 15.37% |
| 2020 FY | 126.95 Million USD | 12.29% |
| 2020 Q1 | 21.51 Million USD | -35.05% |
| 2020 Q2 | 34.66 Million USD | 61.11% |
| 2020 Q4 | 30.76 Million USD | -23.07% |
| 2019 Q2 | 32.72 Million USD | 78.45% |
| 2019 FY | 113.05 Million USD | 1.86% |
| 2019 Q1 | 18.34 Million USD | -29.17% |
| 2019 Q4 | 33.12 Million USD | 14.79% |
| 2019 Q3 | 28.86 Million USD | -11.82% |
| 2018 Q3 | 28.01 Million USD | -8.87% |
| 2018 Q2 | 30.73 Million USD | 16.64% |
| 2018 Q1 | 26.35 Million USD | 92.94% |
| 2018 Q4 | 25.89 Million USD | -7.56% |
| 2018 FY | 110.99 Million USD | 93.76% |
| 2017 Q4 | 13.65 Million USD | -14.43% |
| 2017 FY | 57.28 Million USD | -37.2% |
| 2017 Q3 | 15.96 Million USD | -8.1% |
| 2017 Q2 | 17.36 Million USD | 68.67% |
| 2017 Q1 | 10.29 Million USD | -28.09% |
| 2016 FY | 91.22 Million USD | 550.83% |
| 2016 Q2 | 10.25 Million USD | 112.46% |
| 2016 Q4 | 14.31 Million USD | -76.84% |
| 2016 Q3 | 61.82 Million USD | 503.12% |
| 2016 Q1 | 4.82 Million USD | -29.78% |
| 2015 Q4 | 6.87 Million USD | 75.46% |
| 2015 FY | 14.01 Million USD | -29.47% |
| 2015 Q3 | 3.91 Million USD | 60.69% |
| 2015 Q2 | 2.43 Million USD | 230.22% |
| 2015 Q1 | 738 Thousand USD | -83.05% |
| 2014 Q2 | 3.2 Million USD | 120.6% |
| 2014 Q1 | -15.54 Million USD | 30.63% |
| 2014 Q4 | 4.35 Million USD | -84.37% |
| 2014 FY | 19.87 Million USD | 121.54% |
| 2014 Q3 | 27.85 Million USD | 770.02% |
| 2013 FY | -92.27 Million USD | -99.36% |
| 2013 Q4 | -22.4 Million USD | 7.01% |
| 2013 Q3 | -24.09 Million USD | 11.92% |
| 2013 Q2 | -27.35 Million USD | -48.57% |
| 2013 Q1 | -18.41 Million USD | -36.28% |
| 2012 Q2 | -10.01 Million USD | -7.93% |
| 2012 Q1 | -9.27 Million USD | -111.32% |
| 2012 Q3 | -13.48 Million USD | -34.64% |
| 2012 Q4 | -13.51 Million USD | -0.22% |
| 2012 FY | -46.28 Million USD | -182.65% |
| 2011 Q3 | -9.73 Million USD | -31.95% |
| 2011 Q4 | 81.98 Million USD | 942.26% |
| 2011 Q1 | -11.04 Million USD | -28.89% |
| 2011 FY | 56 Million USD | 245.6% |
| 2011 Q2 | -7.37 Million USD | 33.23% |
| 2010 Q4 | -8.57 Million USD | 0.0% |
| 2010 FY | -38.46 Million USD | -8461.52% |
| 2009 FY | 460 Thousand USD | 101.37% |
| 2009 Q4 | -8.18 Million USD | 0.0% |
| 2008 FY | -33.48 Million USD | -93.83% |
| 2007 FY | -17.27 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Theratechnologies Inc. | -23.95 Million USD | 105.493% |
| Harrow Health, Inc. | -24.41 Million USD | 105.391% |
| Dynavax Technologies Corporation | -6.38 Million USD | 120.598% |
| Biofrontera Inc. | -20.13 Million USD | 106.537% |
| Cronos Group Inc. | -73.96 Million USD | 101.779% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 127.218% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 100.131% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 103.119% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 94.497% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 120.958% |
| Radius Health, Inc. | -25.79 Million USD | 105.103% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 121.353% |
| DURECT Corporation | -27.62 Million USD | 104.764% |
| ProPhase Labs, Inc. | -16.78 Million USD | 107.842% |
| Safety Shot Inc | -15.08 Million USD | 108.725% |
| Phibro Animal Health Corporation | 2.41 Million USD | 45.53% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 142.472% |
| Alvotech | -551.73 Million USD | 100.239% |
| Assertio Holdings, Inc. | -331.94 Million USD | 100.396% |
| Rockwell Medical, Inc. | -8.43 Million USD | 115.594% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 129.205% |
| Procaps Group S.A. | 42.54 Million USD | 96.906% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 100.942% |
| SCYNEXIS, Inc. | 67.04 Million USD | 98.037% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 108.306% |
| Viatris Inc. | 54.7 Million USD | 97.594% |
| OptiNose, Inc. | -35.48 Million USD | 103.709% |
| SIGA Technologies, Inc. | 68.06 Million USD | 98.067% |
| Tilray Brands, Inc. | -244.98 Million USD | 100.537% |
| PetIQ, Inc. | 2.13 Million USD | 38.245% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 129.205% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 99.473% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -732.737% |
| Alimera Sciences, Inc. | -20.13 Million USD | 106.537% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 97.267% |
| Silver Spike Investment Corp. | 7.34 Million USD | 82.071% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 119.961% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 73.387% |
| Journey Medical Corporation | -3.85 Million USD | 134.155% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 116.121% |
| Alpha Teknova, Inc. | -36.78 Million USD | 103.578% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 107.352% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 89.045% |
| PainReform Ltd. | -9.34 Million USD | 114.084% |
| Cosmos Health Inc. | -18.54 Million USD | 107.097% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 100.821% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 112.804% |
| Embecta Corp. | 70.4 Million USD | 98.131% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 130.592% |
| Talphera, Inc. | -18.39 Million USD | 107.153% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 96.863% |
| Incannex Healthcare Limited | -18.45 Million USD | 107.129% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 106.561% |
| Shineco, Inc. | -22.44 Million USD | 105.862% |
| Procaps Group, S.A. | 42.54 Million USD | 96.906% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 92.992% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 116.722% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 99.597% |
| Alvotech | -551.73 Million USD | 100.239% |
| Hempacco Co., Inc. | -13.12 Million USD | 110.026% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 96.308% |
| Bright Green Corporation | -13.12 Million USD | 110.025% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 100.629% |
| Kamada Ltd. | 8.28 Million USD | 84.114% |
| Indivior PLC | 2 Million USD | 34.2% |
| Evoke Pharma, Inc. | -7.79 Million USD | 116.888% |
| Flora Growth Corp. | -57.03 Million USD | 102.307% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 106.561% |
| Evolus, Inc. | -61.68 Million USD | 102.133% |
| HUTCHMED (China) Limited | 100.78 Million USD | 98.694% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 99.043% |
| Akanda Corp. | -32.27 Million USD | 104.077% |